How should I manage a 68-year-old man with resistant hypertension (blood pressure in the 150 mmHg systolic/90 mmHg diastolic range) who is already taking lisinopril 20 mg daily, hydrochlorothiazide 25 mg daily, carvedilol (Coreg) 12.5 mg twice daily, and amlodipine 5 mg daily?

Management of Resistant Hypertension in a 68-Year-Old Man

Add spironolactone 25 mg daily as your fourth-line agent to this patient's regimen, as this is the most evidence-based intervention for resistant hypertension and provides the greatest blood pressure reduction. 1

Initial Assessment and Optimization

Before adding a fourth agent, you must address several critical issues:

1. Confirm True Resistant Hypertension

• Obtain 24-hour ambulatory blood pressure monitoring to exclude white-coat hypertension, which accounts for approximately 37.5% of apparent resistant hypertension cases 2
• If ABPM unavailable, use home blood pressure monitoring (target <135/85 mmHg) 3
• Assess medication adherence directly - nonadherence affects approximately 50% of patients with apparent resistant hypertension 4, 2

2. Optimize Current Regimen

Critical medication adjustments needed:

• Switch hydrochlorothiazide 25 mg to chlorthalidone 12.5-25 mg daily - thiazide-like diuretics (chlorthalidone or indapamide) are superior to HCTZ and maintain efficacy down to eGFR 30 mL/min/1.73m² 5, 2
• Increase amlodipine from 5 mg to 10 mg daily - current dose is submaximal 6
• Consider increasing lisinopril to 40 mg daily if tolerated - 20 mg may be suboptimal
• Verify Coreg dosing - for hypertension, the FDA-approved dose is 6.25-25 mg twice daily (current 12.5 mg appears to be once daily dosing, which is incorrect) 6

3. Address Lifestyle and Secondary Causes

Reinforce lifestyle modifications:

• Sodium restriction to <1500 mg/day (most critical intervention) 1, 5
• Weight loss if BMI >25
• Limit alcohol consumption
• 150 minutes/week aerobic exercise 2

Screen for secondary hypertension:

• Primary aldosteronism (5-25% of resistant hypertension) 2
• Obstructive sleep apnea 7, 5
• Renal artery stenosis
• Check for BP-exacerbating medications: NSAIDs, decongestants, SNRIs 2

Fourth-Line Pharmacologic Treatment

Primary Recommendation: Spironolactone

Start spironolactone 25 mg daily (can increase to 50 mg if needed and tolerated) 1, 5

Evidence supporting this choice:

• Network meta-analysis of 24 RCTs (3,485 patients) showed spironolactone reduces office SBP by -13.3 mmHg (95% CI -17.89 to -8.72) and 24-hour ambulatory SBP by -8.46 mmHg (95% CI -12.54 to -4.38) 2
• The 2024 ESC Guidelines specifically recommend spironolactone as first-choice fourth-line agent 1
• Most effective fourth-line option across multiple guidelines 3, 5

Prerequisites before starting:

• eGFR ≥45 mL/min/1.73m² (some sources allow ≥30) 5, 2
• Serum potassium ≤4.5 mmol/L 2

Monitoring requirements:

• Recheck potassium and creatinine in 1-2 weeks, then monthly for 3 months
• Watch for hyperkalemia (most common adverse effect)
• Monitor for gynecomastia in men

Alternative Fourth-Line Agents (if spironolactone contraindicated/not tolerated)

In order of preference per 2024 ESC Guidelines 1:

1. Eplerenone 50-100 mg daily - selective MRA with less gynecomastia risk
2. Amiloride 5-10 mg daily - potassium-sparing diuretic
3. Bisoprolol 5-10 mg daily - if heart rate >70 bpm (note: patient already on beta-blocker) 5
4. Doxazosin 4-8 mg daily - alpha-blocker 1, 5

Fifth-Line Options (If BP Still Uncontrolled)

If blood pressure remains uncontrolled after optimizing the above:

1. Add bisoprolol (if not already using adequate beta-blockade and heart rate >70 bpm) 5
2. Add hydralazine 25 mg three times daily, titrate to maximum dose 5
3. Consider minoxidil 2.5 mg 2-3 times daily as final pharmacologic step (requires concurrent beta-blocker and loop diuretic) 5
4. Refer to hypertension specialist 1, 5

Blood Pressure Targets

Target BP for this 68-year-old: <130/80 mmHg 3

• The 2024 ESC Guidelines recommend 120-129 mmHg for most patients if tolerated 1
• Individualize based on frailty status 3

Common Pitfalls to Avoid

1. Using HCTZ instead of chlorthalidone/indapamide - HCTZ is less effective in resistant hypertension
2. Inadequate diuretic therapy - most common cause of treatment failure 7
3. Not checking adherence - affects 31-50% of apparent resistant hypertension 4
4. Missing secondary hypertension - particularly primary aldosteronism
5. Incorrect Coreg dosing - verify twice-daily administration 6
6. Adding spironolactone without checking potassium/renal function - can cause life-threatening hyperkalemia

Device-Based Therapy

Renal denervation may be considered only after exhausting pharmacologic options, in high-volume centers, and after shared decision-making 1. Meta-analysis shows modest benefit: 24-hour ambulatory SBP reduction of -4.4 mmHg (95% CI -6.1 to -2.7) 2. This remains investigational and should not replace optimal medical therapy.